From the FDA Drug Label
ZITUVIO is a prescription medicine used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. ZITUVIO is not for people with type 1 diabetes.
Zituvio med is used to improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise.
- It is not recommended for patients with type 1 diabetes mellitus.
- The medication has not been studied in patients with a history of pancreatitis 1.
From the Research
Zituvio med is not mentioned in the provided evidence, however, based on the available information, it appears that the question is referring to a medication, and the most relevant information is related to mepolizumab, which is used to prevent exacerbations of COPD with an eosinophilic phenotype. The medication in question is likely related to respiratory diseases, and the most recent and highest quality study available is related to mepolizumab 2.
- The study found that mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in patients with COPD and an eosinophilic phenotype.
- The typical dosing regimen for mepolizumab involves a 100 mg subcutaneous injection every 4 weeks.
- Common side effects may include adverse events similar to those in the placebo group.
- Patients should be monitored for health-related quality of life and symptoms during treatment. It is essential to note that the provided evidence does not directly mention Zituvio med, and the information provided is based on the most recent and highest quality study available, which is related to mepolizumab 2.
- Other studies, such as those related to exercise-based cardiac rehabilitation 3 and COVID-19 vaccination 4, are not directly relevant to the question and are not considered in this response.